[Editorial] Stem cell dollars flow; But grant process is needlessly shrouded
By Sacramento Bee,
Sacramento Bee
| 02. 12. 2007
California's stem cell research institute has received little attention of late, and agency officials probably prefer it that way. But while the media have been off covering sex scandals involving mayors and astronauts, the Institute for Regenerative Medicine has been quietly preparing, for the first time in its two-year history, to dispense millions of public dollars for embryonic stem cell research.
This week, on Thursday and Friday, the institute's oversight committee will meet in San Francisco to decide on roughly $24 million in grants for new stem cell researchers with innovative ideas. While that may be pocket change compared with the $3 billion that voters authorized when they endorsed Proposition 71 in 2004, this initial research funding is historic, and other grants totaling about $100 million will soon follow this year.
Taxpayers curious about how their money will be spent can go to the institute's Web site -- www.cirm.ca.gov/publicsummaries/PublicList.html -- to see the 30 scientific proposals recommended for funding. The site also includes 200 other projects that didn't make the cut, with summaries and scientific assessments -- some of them...
Related Articles
By Editors, Nature | 08.18.2026
Shinya Yamanaka doesn’t see himself as a celebrity. But people do recognize the stem-cell researcher when he’s out for a run, often while training for a marathon, on the streets of Kyoto, Japan.
Many of them call out words of...
By Jessica Hamzelou, MIT Technology Review | 07.30.2026
As of this week in Montana, any biotech company with an experimental drug has a clear path to selling it to consumers. Companies whose drugs have been through preliminary testing—sometimes in as few as 10 healthy people—can pay $12,500 to...
By Carl Zimmer and Marco Hernandez , The New York Times | 07.01.2026
Scientists have long dreamed of discovering the alchemy by which chemicals can be turned into life. On Wednesday, a team at the University of Minnesota announced that it had taken a major step toward that vision.
Blending together dozens of...
By Marisa Flook , BioNews | 06.29.2026
An anti-ageing gene therapy not approved by the US Food and Drug Administration (FDA) is set to be offered by an American company at overseas clinics outside of US jurisdiction.
The treatment, developed by Minicircle from Austin, Texas, uses a...